<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>这些药物可能会预防严重COVID These Drugs Might Prevent Severe COVID</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script>
<script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">These Drugs Might Prevent Severe COVID<br/>这些药物可能会预防严重COVID </h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2020-12-22 04:51:25</div><div class="story_img_container"><a href="http://img2.diglog.com/img/2020/12/95853e0b1edd8905627fa256305a71b3.jpg"><img src="http://img2.diglog.com/img/2020/12/95853e0b1edd8905627fa256305a71b3.jpg" class="img-fluid my_story_img" onerror="this.style.display='none'"></a></div><div class="page_narrow text-break page_content"><p>In the year since the COVID pandemic began, glimmers of hope have come on the horizon. Vaccines are on the way, and the percentage of patients who die has fallen in many places as doctors have learned how to save the sickest patients.</p><p>自COVID大流行开始以来的这一年，一线希望就已经浮出水面。疫苗即将来临，随着医生学会了如何挽救最病的病人，死亡的病人百分比在许多地方都在下降。</p><p>  These successes are not enough—and they overshadow the more limited progress made toward developing drugs that could prevent mild cases of the disease from worsening. Such treatments are urgently needed because many people will get sick with COVID until vaccines induce enough herd immunity in the population to keep the infections under control.</p><p>  这些成功还远远不够，它们掩盖了在开发可预防轻度疾病恶化的药物方面取得的有限进展。迫切需要这种治疗方法，因为许多人会因感染COVID而生病，直到疫苗在人群中引起足够的畜群免疫力以控制感染为止。</p><p>  Antivirals and other drugs for early-stage illness could ideally prevent hospitalizations, shorten the duration of infectiousness and limit long-term complications from COVID. They may also prove useful against other threatening coronaviruses in the future. As of this writing, only two therapies for early COVID are available, and both of them come with major logistical challenges. But many other potential treatments are being developed that could save people from the worst outcomes.</p><p>  抗病毒药和其他用于早期疾病的药物可以理想地预防住院，缩短感染时间并限制COVID引起的长期并发症。将来它们也可能被证明对其他威胁性冠状病毒有用。在撰写本文时，只有两种针对早期COVID的疗法可用，并且两种疗法都面临着重大的后勤挑战。但是，正在开发许多其他可能的治疗方法，这些方法可以使人们免于最坏的后果。</p><p>  Regeneron’s monoclonal antibody combination for mild-to-moderate COVID, which was granted an emergency use authorization by the Food and Drug Administration in November, requires an hour-long intravenous infusion and another hour of monitoring for possible side effects. A second drug, the antiviral remdesivir, has shown promise in newly infected patients, but it requires five days of intravenous therapy. Demand for these medications, which were both administered to President Donald Trump and his allies during their illnesses, far outstrips current supplies. What doctors need are safe and effective treatments for early cases that they can give in outpatient settings “without overwhelming the health care system,” says William Fischer, a pulmonologist at the University of North Carolina School of Medicine.</p><p>  Regeneron用于轻度至中度COVID的单克隆抗体组合已于11月获得美国食品药品监督管理局（FDA）的紧急使用授权，它需要进行一小时的静脉输注，并需要另外一小时的监测以监测可能的副作用。第二种药物抗病毒药物瑞姆昔韦已经在新感染的患者中显示出了希望，但需要静脉注射五天。对这些药物的需求远远超过了目前的供应量，这些药物都是在唐纳德·特朗普总统及其盟友生病期间给予的。北卡罗来纳大学医学院的肺科医师William Fischer说，医生需要的是对早期病例而言安全有效的治疗方法，可以在不使卫生保健系统不堪重负的情况下在门诊提供治疗。</p><p>  Drug development efforts aimed at treatments to contain the novel coronarvirus, or SARS-CoV-2, soon after infection are now ramping up. Physicians have a limited window of opportunity to hit the virus while it continues to replicate. Patients typically clear SARS-CoV-2 from their lungs and nasal passages within seven to 10 days, and after that, treatments aimed at curbing the pathogen become less effective. Even as viral loads plummet, immune reactions against SARS-CoV-2 can, in some patients, trigger out-of-control inflammation that destroys healthy lung tissue. At that point, treatment shifts toward drugs for severe COVID, such as dexamethasone, which ideally keep the inflammation in check.</p><p>  旨在在感染后不久就遏制新型冠状病毒或SARS-CoV-2的治疗药物的研发工作正在迅速开展。当病毒继续复制时，医生感染该病毒的机会窗口有限。患者通常会在7到10天内从肺和鼻腔清除SARS-CoV-2，此后，旨在遏制病原体的治疗效果较差。即使病毒载量急剧下降，在某些患者中，针对SARS-CoV-2的免疫反应仍可能引发失控的炎症，从而破坏健康的肺组织。那时，治疗转向重度COVID药物，例如地塞米松，理想情况下可控制炎症。</p><p>  In an interview with  Scientific American, Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, described the desired  characteristics of early COVID treatments. “My overwhelming preference is for direct-acting antiviral agents that can be administered orally” and that suppress the virus completely within a week or less, he said. “That, to me, is the highest priority.”</p><p>  美国国家过敏和传染病研究所所长安东尼·富奇在接受《科学美国人》采访时，描述了早期COVID治疗的理想特征。他说：“我压倒性的首选是可以口服的直接作用抗病毒药”，并且可以在一周或更短的时间内完全抑制这种病毒。 “对我来说，这是最高优先事项。”</p><p>  Scientists have begun on differing paths to search for these drugs. By using machine-learning algorithms, they can quickly scour chemical databases for compounds with structural properties that might work against SARS-CoV-2. Promising candidates will then move from computer-modeling studies to research in human cell lines and experimental animals. Researchers are also using new protocols designed to shuttle drugs quickly from early- to late-stage clinical trials in outpatient settings. This approach “allows us to assess more compounds in a rapid, efficient way, though we are not rushing the scientific process for any of them,” says Rachel Bender Ignacio, a physician-scientist at the Fred Hutchinson Cancer Research Center in Seattle.</p><p>  科学家们已经开始寻找不同途径寻找这些药物。通过使用机器学习算法，他们可以快速搜索化学数据库中具有可能抵御SARS-CoV-2的结构特性的化合物。然后有希望的候选人将从计算机建模研究转向对人类细胞系和实验动物的研究。研究人员还使用了旨在在门诊环境中从早期到后期临床试验快速穿梭药物的新方案。西雅图的弗雷德·哈钦森癌症研究中心的医师科学家雷切尔·本德·伊格纳西奥（Rachel Bender Ignacio）说，这种方法“使我们能够快速，有效地评估更多的化合物，尽管我们并不急于对其进行科学处理。” </p><p>  Some of those drugs are repurposed medications that were initially developed for other diseases. Remdesivir, for instance, was targeted at Ebola and tested in human safety trials before being used later as a drug for COVID.</p><p>其中一些药物是重新开发的药物，最初是针对其他疾病开发的。例如，Remdesivir的目标是埃博拉病毒，并在人类安全性试验中进行了测试，然后才用作COVID的药物。</p><p>  One of the current leading contenders for treating mild COVID is an antiviral pill that was previously developed for influenza. At first called EIDD-2801,  the drug was found to protect mice from severe lung disease caused by two other coronaviruses—SARS-CoV and MERS-CoV. These results were from a study by researchers at the University of North Carolina at Chapel Hill (UNC) and their colleagues that was published in April. Based on those findings, a Miami-based company, Ridgeback Biotherapeutics, licensed EIDD-2801, now called molnupiravir, for safety testing in people. Ridgeback has since partnered with Merck on a mid- to late-stage clinical trial, expected to wrap up next year, to assess molnupiravir in nonhospitalized and hospitalized COVID patients.*</p><p>  目前治疗轻度COVID的主要竞争者之一是一种抗病毒药丸，以前是针对流感而开发的。起初名为EIDD-2801的药物被发现可以保护小鼠免受其他两种冠状病毒（SARS-CoV和MERS-CoV）引起的严重肺部疾病的侵害。这些结果来自北卡罗来纳大学教堂山分校（UNC）的研究人员及其同事的一项研究，该研究于4月发表。基于这些发现，位于迈阿密的一家名为Ridgeback Biotherapeutics的公司获得了EIDD-2801（现在称为molnupiravir）的许可，用于人体安全性测试。从那时起，Ridgeback与默克（Merck）合作进行了一项中晚期临床试验，预计将于明年结束，以评估未住院和住院的COVID患者中的莫洛哌韦（*）</p><p>  Richard Plemper, a molecular virologist and biochemist at Georgia State University, has been working with the compound for years. He recently published a study showing that  molnupiravir blocks SARS-CoV-2 transmission in ferrets, animals scientists use to model human coronavirus exposures. “If the ferret data are indicative of what the drug can do in people, then it suggests we’ll be able to therapeutically interrupt human transmission chains in people,” he says. “And that would be a real game changer.”</p><p>  乔治亚州立大学的分子病毒学家和生物化学家Richard Plemper多年来一直在使用这种化合物。他最近发表了一项研究，表明莫洛匹韦韦可以阻止雪貂在动物雪貂中传播SARS-CoV-2，科学家们用它们来模拟人类冠状病毒的暴露。他说：“如果雪貂数据表明该药物可以在人体内发挥作用，那么这表明我们将能够在治疗上中断人体内的人类传播链。” “那将是一个真正的游戏规则改变者。”</p><p>  Repurposing existing drugs can also yield some surprises by finding ones that are not logical candidates to work against COVID-19. Fluvoxamine, a pill used for treating anxiety disorders, shows some promise in treating early COVID. Researchers at Washington University in St. Louis randomized 152 patients to fluvoxamine or a placebo and reported in November  that  none of the 80 patients who got the drug experienced worsening symptoms. By contrast, six patients in the placebo group became severely ill,  and four were hospitalized. Psychiatrist Angela Reiersen, a Washington University in St. Louis psychiatrist who conducted the study,  explains that fluvoxamine acts on a protein called the sigma-1 receptor, which dampens the body’s inflammatory responses to viral infection. She is now launching a larger trial across the U.S. and Canada. “We’d like to enroll people as soon as they have a positive test and some minor symptoms,” Reiersen says. “The goal is treat before week two, which is when patients generally start to deteriorate.”</p><p>  通过找到不符合COVID-19的合理候选药物，重新利用现有药物也可能会带来一些惊喜。氟伏沙明（一种用于治疗焦虑症的药）在治疗早期COVID中显示出一定的希望。圣路易斯华盛顿大学的研究人员将152名患者随机分配给氟伏沙明或安慰剂，并在11月报告称，服用该药的80名患者中没有一名出现症状恶化的情况。相比之下，安慰剂组中有6名患者重病，有4例住院。负责这项研究的华盛顿大学精神病学家，精神病学家安吉拉·赖尔森（Angela Reiersen）解释说，氟伏沙明作用于一种称为sigma-1受体的蛋白质，该蛋白质可抑制人体对病毒感染的炎症反应。她现在正在美国和加拿大进行更大的审判。 Reiersen说：“我们希望在人们的检测结果呈阳性并且出现一些轻微症状时尽快注册他们。” “目标是在第二周开始治疗，这是患者通常开始恶化的时候。”</p><p>  Utilizing therapies that were initially developed for other purposes is not the only strategy. Drug designers have also come up with a computer-generated synthetic protein that disables SARS-CoV-2 before it gains a foothold in the body. At the University of Washington, researchers have devised from scratch proteins that bind to a spot on the virus’s spikelike protrusions. These proteins—called mini binders— deflect the virus more effectively than antibodies in human cells, according to David Baker, a computational biologist who was senior author of the study. Baker says that in unpublished research, mini binders protected hamsters against SARS-CoV-2 infection. “We see this as a prophylactic nasal spray that you could use, say, if you’re going to the airport or if you’re a medical worker going into a risky situation,” he says. Baker predicts that mini binders could enter human clinical trials against SARS-CoV-2 within six months.</p><p>  使用最初用于其他目的的疗法并不是唯一的策略。药物设计者还想出了一种计算机生成的合成蛋白，该蛋白在进入人体之前先使SARS-CoV-2失效。在华盛顿大学，研究人员从零开始设计了与病毒尖峰样突起上的斑点结合的蛋白质。这项研究的资深作者，计算生物学家戴维·贝克（David Baker）说，这些蛋白质（称为微型结合物）比人类细胞中的抗体更有效地偏转病毒。贝克说，在未发表的研究中，迷你粘合剂可以保护仓鼠免受SARS-CoV-2感染。他说：“我们认为这是一种预防性鼻喷雾剂，例如，如果您要去机场或者是有危险的医务人员，可以使用它。”贝克预测，迷你粘合剂可能会在六个月内进入针对SARS-CoV-2的人体临床试验。</p><p>  In his interview with  Scientific American, Fauci said that a single broad-spectrum drug that protects against many kinds of viruses is probably “a bridge too far.” Yet what can be developed is a drug that works against multiple pathogens within the same viral family—perhaps one against multiple coronaviruses.</p><p>  Fauci在接受《科学美国人》采访时说，一种可以抵御多种病毒的广谱药物可能是“一座遥不可及的桥梁”。然而，可以开发出一种针对同一病毒家族中多种病原体的药物-可能针对多种冠状病毒。</p><p>  Virologist Ralph Baric and his team at UNC have spent years working toward that goal. Much of the research is devoted to screening compounds against severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) and SARS-like preepidemic bat coronaviruses in human cells and experimental animals. “When we started screening, we found some compounds that would only work against SARS and some that only worked against MERS,” Baric says. “Then we found one that worked against  both.” That drug was remdesivir.</p><p>  病毒学家拉尔夫·巴里奇（Ralph Baric）和他在UNC的团队为实现该目标花费了多年时间。许多研究致力于在人细胞和实验动物中筛选针对严重急性呼吸综合症（SARS），中东呼吸综合症（MERS）和SARS样流行性蝙蝠冠状病毒的化合物。 “当我们开始筛查时，我们发现了一些仅对SARS有效的化合物，而另一些仅对MERS有效的化合物，” Baric说。 “然后，我们发现了一个对两者都不利的东西。”那药是雷姆昔韦。 </p><p>  In follow-up research, Baric and his collaborator Timothy Sheahan of UNC showed  the drug could also inhibit SARS-CoV-2 in human lung cells and engineered mice. Yet remdesivir’s Achilles’ heel, Baric says, “has always been that it has to be given intravenously to people, which limits uses to hospitalized patients.” In Baric’s view, that explains the drug’s inconsistent track record when it comes to speeding up COVID recovery rates: Doctors are often reluctant to admit people for treatment, he says, especially when beds are in short supply. By the time treatments begin, the virus is cleared, “and then it’s too late,” Baric adds. Remdesivir’s manufacturer, Gilead Sciences, is now developing an inhalable form of the drug that should be easier to administer in outpatient settings.</p><p>在后续研究中，Baric和他的UNC的合作者Timothy Sheahan显示，该药还可以抑制人肺细胞和工程小鼠的SARS-CoV-2。巴里奇说，然而，伦德西韦的阿喀琉斯之heel“一直以来都是必须静脉注射给人们，这限制了住院病人的使用。”在巴里奇（Baric）看来，这解释了该药在提高COVID回收率方面的不一致记录：他说，医生经常不愿接纳患者接受治疗，尤其是在床位短缺的情况下。在治疗开始时，病毒已清除，“然后为时已晚，” Baric补充说。 Remdesivir的制造商吉利德科学公司（Gilead Sciences）现在正在开发一种可吸入形式的药物，这种药物应该更容易在门诊患者中使用。</p><p>  Baric contends that evidence that remdesivir, molnupiravir and other compounds are able to block multiple coronaviruses suggests that broad-based antivirals are feasible. “Imagine putting a concerted effort into developing inhibitors for the viral families most likely to cause pandemic disease outbreaks around the globe,” he says. “If we had those drugs on the shelf and ready to use immediately in an outbreak setting, we could save a ton of lives.”</p><p>  Baric认为，有证据表明雷姆昔韦，molnupiravir和其他化合物能够阻断多种冠状病毒，这表明广泛的抗病毒药是可行的。他说：“想像一下，共同努力为最有可能导致全球大流行性疾病暴发的病毒家族开发抑制剂。” “如果我们将这些药物放在架子上，并准备在疫情中立即使用，我们可以挽救很多生命。”</p><p>  *This story was updated to specify that patients of Ridgeback Biotherapeutics were both nonhospitalized and hospitalized patients.</p><p>  *此故事已更新，以指定Ridgeback Biotherapeutics的患者均为非住院患者和住院患者。</p><p>  Read more about the coronavirus outbreak from Scientific American  here. And read coverage from our international network of magazines  here.</p><p>  在这里阅读更多有关《科学美国人》中冠状病毒爆发的信息。并在此处阅读我们国际杂志网络的报道。 </p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://www.scientificamerican.com/article/these-drugs-might-prevent-severe-covid1/">https://www.scientificamerican.com/article/these-drugs-might-prevent-severe-covid1/</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/可能/">#可能</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/prevent/">#prevent</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/药物/">#药物</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/分享/">#分享</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy; 2020 diglog.com </div></div></body></html>